Abstract:10045 Background: GIST has a high recurrenc e rate and disease-related mortality even after completed resection of primary tumor. Imatinib(IM) has shown tremendous efficacy in treating patients with metastatic and unresectable GISTs. The primary objective of the study was to evaluate the efficacy and safety of adjuvant post-surgical therapy with IM in GIST patients who had high risk to relapse. Methods: This prospective, open-label, multi-center trial was conducted in 16 hospitals in China. Patient eligibility criteria included patients >18 years old, diagnosed with CD117+ GIST of either =5cm macroscopic tumor size or = 5/50 HPF in mitosis count pathologically. Patients were started on IM 400mg/d for at least 12 months within 4 weeks after completed resection. Primary endpoint was relapse or metastasis rates. Secondary endpoints were disease free survival (DFS), overall survival rate (OSR) and quality of life. From Aug 16 2004 to Sep 13 2005, 57 patients (34 men) enrolled in the trial and average age of patients was 50.6. The primary tumor location was stomach in 50.9%, small intestine in 38.6%. Tumors size was >5cm in 92.9% of patients, and 73.7% of patients had a mitosis count over 5/50 HPF. The majority of patients tested positive for CD34 (82.5%) and negative SMA, S-100 and Desmin results. Results: Of 57 patients, as of date of data cut-off (Dec 31, 2006) 51 patients were included in the ITT analysis and 43 patients (75.4%) finished at least 12 months of IM treatment, and Tumor relapses or metastasis were identified in 2 patients (3.92%) 350 and 680 days post-operation. No death was reported. Median DFS was 385 days. 57.89% of the safety population had adverse events. No serious adverse event reported. 50.88% of the safety population had adverse events related to the treatment of IM based on the determination of investigators. The score in quality of life showed no statistically significant difference between the baseline and the follow-up visits. Conclusions: IM is a promising adjuvant post-surgical therapy in patients with high risk of relapsing GIST. But the optimal doses and duration of adjuvant treatment are still unknown. On the basis of this study, a multi-institutional randomized controlled trial will be necessary. No significant financial relationships to disclose.

Is 3-Years Duration of Adjuvant Imatinib Mesylate Treatment Sufficient for Patients with High-Risk Gastrointestinal Stromal Tumor? A Study Based on Long-Term Follow-Up

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Followed by Sunitinib Compared to Followed by Imatinib-a Multi-Center Cohort Study

Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors: a Retrospective Cohort Study.

[Efficacy Observation on Imatinib Adjuvant Therapy with Longer Duration in Patients with Gastrointestinal Stromal at Intermediate or High Risk of Recurrence].

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?

Risk of Disease Recurrence and Mortality in Gastrointestinal Stromal Tumor (gist) Patients Receiving Short-Term Versus Long-Term Imatinib Adjuvant Therapy: A Chart Review Analysis.

Efficacy Analysis of Adjuvant Therapy with Imatinib for Gastric Intermediate-Risk Gastrointestinal Stromal Tumor.

Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study

Efficacy And Safety Of Adjuvant Post-Surgical Therapy With Imatinib In Patients With High Risk Of Relapsing Gist

Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.

Safety, effectiveness and the optimal duration of preoperative imatinib in locally advanced gastric gastrointestinal stromal tumors: A retrospective cohort study

Gastrointestinal stromal tumor: 15-years’ experience in a single center

Postoperative imatinib treatment in gastric intermediate-risk gastrointestinal stromal tumors

Investigation Of Gastrointestinal Stromal Tumor (Gist) Care Management In Gist Patients (Pts) Receiving Short-Term Versus Long-Term Imatinib (Im) Adjuvant Therapy: A Chart Review Analysis.

Postoperative Imatinib in Patients with Intermediate Risk Gastrointestinal Stromal Tumor

[Updates on Adjuvant Therapy in Gastrointestinal Stromal Tumor].

Influence of imatinib mesylate in the treatment of high-risk patients with gastrointestinal stromal tumors

A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse